Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 16Hodgkin Disease 13Lymphoma, Non-Hodgkin 11Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Leukemia, Biphenotypic, Acute 8Leukemia 8Burkitt Lymphoma 7Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Rhabdomyosarcoma 4Medulloblastoma 4Lymphoma, Follicular 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Temozolomide 12Vincristine 9Irinotecan 8Cyclophosphamide 8cabozantinib 6X-Rays 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Etoposide 5regorafenib 4fludarabine 4Radiotherapy 4Phantoms, Imaging 4Ifosfamide 4Doxorubicin 4Radiation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2liposomal doxorubicin 2ivosidenib 2irinotecan sucrosofate 2etoposide phosphate 2abemaciclib 2Zoledronic Acid 2Topotecan 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Filgrastim × 1 year × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡